Malignant Melanoma: Advances in Diagnosis, Prognosis, and Treatment

The detection of cutaneous melanoma still largely relies on clinical suspicion, skin biopsy,
and histopathologic evaluation. New technologies are being evaluated to bypass the skin
biopsy in the detection of melanoma. The quest for reliable biomarkers, with respect to
subclinical detection, prognosis, and predicting treatment response, is longstanding and
ongoing. New therapies have been developed for metastatic disease, including targeted
small molecule inhibitors as well as immune modulators.
Semin Cutan Med Surg 31:45-49 © 2012 Elsevier Inc. All rights reserved.

The detection of cutaneous melanoma still largely relies on clinical suspicion, skin biopsy,
and histopathologic evaluation. New technologies are being evaluated to bypass the skin
biopsy in the detection of melanoma. The quest for reliable biomarkers, with respect to
subclinical detection, prognosis, and predicting treatment response, is longstanding and
ongoing. New therapies have been developed for metastatic disease, including targeted
small molecule inhibitors as well as immune modulators.
Semin Cutan Med Surg 31:45-49 © 2012 Elsevier Inc. All rights reserved.

Purchase this article:

PURCHASE FOR $25

For unlimited access to all issues and articles:

SUBSCRIBE NOW LOG IN TO ACCOUNT

If you do not subscribe to Seminars in Cutaneous Medicine and Surgery, you may purchase instant access for your personal use. Terms and conditions will apply (see Copyright & Terms of Use). If you need assistance, contact Susan Hite ([email protected]).